Skip to NavigationSkip to content

Johnson & Johnson's single-shot COVID-19 vaccine 85% effective

Published on 01/02/21 at 11:14am

Johnson & Johnson has announced that its COVID-19 vaccine candidate is 85% effective in preventing serious symptoms of the disease, after interim analysis of Phase III of its trial.

The shot, which was also 66% successful in preventing moderate to severe COVID-19, only requires one dose rather than two - unlike other vaccines such as the Oxford University/AstraZeneca vaccine currently being administered in the UK.

The study was conducted on 43,783 participants from eight countries, including South Africa, where it was found to be 57% effective against moderate to severe COVID-19. This eases concerns that this, and other vaccines, might be ineffective against a new strain found in the African country.

The Phase III ENSEMBLE study was a randomised, double-blind clinical trial, designed to evaluate the safety and efficacy of the vaccine versus a placebo in adults over 18 years old, with assessment at days 14 and 28. It demonstrated complete protection against COVID-19-related hospitalisation and death 28 days after vaccination.

The candidate can be stored for three months at temperatures of 2-8℃, meaning it can be transported and stored at fridge temperatures. It can remain stable for up to two years at a temperature of -20℃.

The UK has already placed an order for 30 million shots, pending approval by the MHRA . It is expected to cost roughly £7 per dose, about the same price as two doses of the Oxford University/AstraZeneca vaccine.

Paul Stoffels, MD, Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson said: “These topline results with a single-shot COVID-19 vaccine candidate represent a promising moment.

“The potential to significantly reduce the burden of severe disease, by providing an effective and well-tolerated vaccine with just one immunisation, is a critical component of the global public health response.”

 Jack Goddard

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches